ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

In this interview, José A. Joglar, MD, FACC, and Joseph E. Marine MD, MBA, FACC, discuss the top takeaways from the latest atrial fibrillation (AFib) guideline, which provides new and updated recommendations for preventing and optimally managing AFib.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

A study provides new data for patients with genetic heart disease (GHD) and exercise recommendations. For decades, those with GHD were excluded from exercise and sports participation. This has led to poor exercise tolerance, increased risk for CAD and poor outcomes in this group related to reduced fitness.  This study helps frame that those with GHD are unique and as a result, require an individualized approach to care. After expert consultation, patients with GHD can often be safe to participate in exercise including competitive sports. This is a first step in the direction of understanding the role of exercise in GHD in the care of patients who wish to exercise.  In this interview, Katherine Martinez, and Matthew Martinez MD, FACC, discuss From JACC: Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death.    Subscribe on Apple Podcasts | Subscribe to ACCEL 

Continuous cardiac monitoring detects brief, asymptomatic, heart rhythm abnormalities in one-third of older individuals and these symptoms are associated with an increased risk of stroke.  The ARTESiA trial clearly demonstrates that use of the blood thinner apixaban reduces patient risk of stroke compared to treatment with aspirin, but is associated with an increased risk of bleeding.  In this interview, Jeff S. Healey, MD, and Thomas F. Deering MD, FACC, discuss AHA Late-Breaker: Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Experts discuss key principles and the importance of risk-based treatment decisions in the ACC 2023 guideline for chronic coronary disease. They also delve into the signs and symptoms that prompt testing for chronic CAD and the impact of new therapies on patient management. The podcast covers recommendations for clinicians to avoid ineffective procedures and therapies, as well as class three recommendations for hormone replacement therapy and certain supplements. Additionally, they address the difficulty of persuading patients about the necessity of repeated testing and emphasize the importance of building trust through clear communication.

To improve our understanding of the basic principles in the treatment and management of patients with chronic heart disease, in this interview, Salim S. Virani, MD, PhD, FACC, and Roger S. Blumenthal, MD, FACC, discuss top takeaways from the ACC 2023 Guideline for Chronic CAD.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Patients with worsening heart failure are at an extraordinarily high risk for mortality and readmission. Early identification and optimal management of these patients can significantly improve patient outcomes. Several clinical trials in these patients have shown benefit with various therapies.  In this interview, Javed Butler, MD, MPH, MBA, FACC, and Matthew Martinez, MD, FACC, discuss Management of Worsening Heart Failure with Reduced Ejection Fraction.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

The SELECT trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (DM), to those without DM. In this interview, Abraham Lincoff, MD, FACC, and Glenn A. Hirsch MD, MHS, FACC, discuss AHA Late-Breaker: SELECT – Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this review, authors discuss how multimodality imaging can help to evaluate the left ventricular remodeling response and improve risk stratification in patients with moderate aortic stenosis.   In this interview, Jeroen J Bax, MD, PhD, FACC, and Matt Cavender, MD, MPH, FACC, discuss JACC review, Managing Patients With Moderate Aortic Stenosis.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Andrew Kates, MD, FACC, and Alison L. Bailey, MD, FACC, discuss the top takeaways in general cardiology from 2023 including ARAMIS, ORBITA-2, and STOP-CA trials.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

While we know that statin treatment reduces the risk of stroke, heart attack and heart deaths in people at moderate-to-high risk, or with high cholesterol, in REPRIEVE statins decreased the risk in those at low-to-moderate risk, and with 'normal' cholesterol levels who would not usually be considered candidates for treatment.   In this interview, Pamela S. Douglas, MD, MACC, and Roger S. Blumenthal MD, FACC, discuss Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL